Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

Journal Articles

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Blood (2014) 123 (12): 1836–1849.

https://doi.org/10.1182/blood-2013-04-497271

Published: 2014

Includes: Supplemental data

Journal Articles

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Stefano Sacchi, MD, Alessia Bari, MD, Tamar Tadmor, MD, Luigi Marcheselli, MS, Samantha Pozzi, MD, Eliana Valentina Liardo, MD, Angela Ferrari, MD, Caterina Stelitano, Paolo G Gobbi, Prof, Luca Baldini, Daniele Vallisa, MD, Emilio Iannitto, MD, Aaron Polliack, MD, Massimo Federico

Blood (2013) 122 (21): 1754.

https://doi.org/10.1182/blood.V122.21.1754.1754

Published: 2013

Journal Articles

Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy

Esther Natalie Oliva, Francesco Albano, Nicola Di Renzo, Vincenzo Pavone, Stefano Molica, Fortunato Morabito, Attilio Guarini, Giuseppe Tarantini, Silvana Capalbo, MD, Emilio Iannitto, Giovanni Quarta, MD, Nicola Cascavilla, Pierfrancesco Tassone, MD, Francesco Iuliano, Roberto Porciello, Paola Casieri, Carmelo Laganà, Francesco Nobile, Giorgina Specchia

Blood (2012) 120 (21): 50623.

https://doi.org/10.1182/blood.V120.21.50623.50623

Published: 2012

Journal Articles

Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy

Blood (2012) 120 (21): 5200.

https://doi.org/10.1182/blood.V120.21.5200.5200

Published: 2012

Journal Articles

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?

Blood (2011) 118 (21): 2638.

https://doi.org/10.1182/blood.V118.21.2638.2638

Published: 2011

Journal Articles

Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY

Blood (2011) 118 (21): 2837.

https://doi.org/10.1182/blood.V118.21.2837.2837

Published: 2011

Journal Articles

Interim 18 f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

Domenica Caramazza, Francesco Dentali, MD, Michele Merli, Giorgia Saccullo, Alessandra Malato, Gerlando Quintini, Emilio Iannitto, Francesco Passamonti, Sergio Siragusa, MD

Blood (2011) 118 (21): 5183.

https://doi.org/10.1182/blood.V118.21.5183.5183

Published: 2011

Journal Articles

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Carlos Montalban, MD, PhD, Victor Abraira, PhD, Luca Arcaini, Eva Domingo-Domenech, MD, Pablo Guisado-Vasco, MD, PhD, Emilio Iannitto, MD, Manuela Mollejo, MD, Estella Matutes, Andrés JM Ferreri, MD, Antonio Salar, MD, PhD, Andrea Carpaneto, MD, Ricardo Pérez, MD, Jose Luis Bello, Miguel Hernandez, Dolores Caballero, MD, Miguel A. Piris, MD, PhD

Blood (2011) 118 (21): 1583.

https://doi.org/10.1182/blood.V118.21.1583.1583

Published: 2011

Journal Articles

How I diagnose and treat splenic lymphomas

Emilio Iannitto, Claudio Tripodo

Blood (2011) 117 (9): 2585–2595.

https://doi.org/10.1182/blood-2010-09-271437

Published: 2011

Journal Articles

Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group

Francesco Maura, Giovanna Cutrona, PhD, Massimo Gentile, Serena Matis, PhD, Monica Colombo, Luca Agnelli, Giacomo Tuana, Rosanna Massara, Fabrizio Loiacono, Simona Pedemonte, Daniele Reverberi, Emanuela Anna Pesce, Marta Lionetti, PhD, Sonia Fabris, PhD, Anna Grazia Recchia, Francesco Di Raimondo, MD, Caterina Musolino, MD, Marco Gobbi, Nicola Di Renzo, MD, Francesca Romana Mauro, Renato Cantaffa, Maura Brugiatelli, MD, Francesco Merli, MD, Simonetta Zupo, Caterina Mammi, Luca Baldini, Francesco Angrilli, MD, Gianni Quintana, Ugo Consoli, MD, Giovanni Bertoldero, MD, Emilio Iannitto, MD, Paolo Di Tonno, Antonio Fragasso, Stefano Molica, MD, Pellegrino Musto, MD, Maria Cristina Cox, Gianluca Festini, Vincenzo Callea, MD, Stefano Sacchi, Giorgio Lambertenghi Deliliers, MD, Robin Foà, MD, Massimo Federico, MD, Agostino Cortelezzi, MD, Fortunato Morabito, Manlio Ferrarini, Antonino Neri, MD

Blood (2010) 116 (21): 2423.

https://doi.org/10.1182/blood.V116.21.2423.2423

Published: 2010

Journal Articles

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Blood (2010) 116 (21): 1360.

https://doi.org/10.1182/blood.V116.21.1360.1360

Published: 2010

Journal Articles

Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study.

Blood (2010) 116 (21): 4613.

https://doi.org/10.1182/blood.V116.21.4613.4613

Published: 2010

Journal Articles

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

Blood (2010) 116 (21): 634.

https://doi.org/10.1182/blood.V116.21.634.634

Published: 2010

Journal Articles

A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.

Blood (2009) 114 (22): 882.

https://doi.org/10.1182/blood.V114.22.882.882

Published: 2009

Journal Articles

External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience.

Blood (2009) 114 (22): 2375.

https://doi.org/10.1182/blood.V114.22.2375.2375

Published: 2009

Journal Articles

Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study.

Blood (2009) 114 (22): 2341.

https://doi.org/10.1182/blood.V114.22.2341.2341

Published: 2009

Journal Articles

A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Roberto Guariglia, Stefano Luminari, Amalia De Renzo, Emilio Iannitto, Matteo Dell’Olio, Samantha Pozzi, Teresa Pierri, Lucia D’Amato, Antonio Traficante, Stefano Sacchi, Pellegrino Musto

Blood (2008) 112 (11): 3054.

https://doi.org/10.1182/blood.V112.11.3054.3054

Published: 2008

Journal Articles

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Emilio Iannitto, MD, Stefano Luminari, MD, Caterina Mammi, MD, Viviana Minardi, Francesco Merli, MD, Francesco Angrilli, MD, Caterina Stelitano, MD, Marina Cesaretti, Giovanni Franco, MD, Angelo M. Carella, MD, Massimo Federico, MD

Blood (2007) 110 (11): 1293.

https://doi.org/10.1182/blood.V110.11.1293.1293

Published: 2007

NARROW

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Are Absolute Monocyte Count and The Lymphocyte-Monocyte Ratio (LMR) Valid Prognostic Factors In Classical Hodgkin Lymphoma? An Evaluation Based On Data From 1079 Patients

Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy

Cytogenetic Analysis in Patients with Newly Diagnosed Myelodysplastic Syndromes in Southern Italy

Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen?

Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY

Interim 18 f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

How I diagnose and treat splenic lymphomas

Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study.

Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells

External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience.

Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study.

A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only